Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)

Yasuhiro Nakamura(University of Tsukuba), Naoya Yamazaki(Tokyo National Hospital), Yoshiyasu Umeda(Saitama Medical University), Natsuki Baba(University of Fukui), Shigeto Matsushita(National Hospital Organization), Yukiko Kiniwa(Shinshu University), Takeo Maekawa(Jichi Medical University), Taiki Isei(Fukuoka University), Osamu Yamasaki(Okayama University), Ryo Tanaka(Kawasaki Medical School), Takashi Inozume(Chiba University), Kotaro Nagase(Saga University), Akira Takahashi, Kenjiro Namikawa(Tokyo Metropolitan Komagome Hospital), Masazumi Onishi(Iwate Medical University), Hiroshi Kato(The University of Osaka), Masaki Otsuka(Shizuoka Cancer Center), Taisuke Matsuya(Asahikawa Medical University), Yukiko Teramoto(Asahikawa Medical University), Noriki Fujimoto(Shiga University of Medical Science), Atsushi Otsuka(Kyoto University), T Onuma(University of Yamanashi), Tatsuya Takenouchi(Niigata Cancer Center Hospital), Dai Ogata(Unknown), Motoo Nomura(Kyoto University), Yutaka Kuwatsuka(Nagasaki University), Shintaro Saito(Gunma University), Takahide Kaneko(Juntendo University Urayasu Hospital), Shusuke Yoshikawa(Kyushu University), Y. Nakai(Mie University), Satoshi Fukushima(Niigata Cancer Center Hospital)
ESMO Open
November 25, 2021
Cited by 57


Related Papers